We met with Julie Graff (Knight Cancer Institute) at ESMO 2019 to discuss unmet needs in the treatment of metastatic castration-resistant prostate cancer and KEYNOTE-641 (NCT03834493), a phase III study of pembrolizumab plus enzalutamide in this patient population.
Questions
1.    What are the current unmet needs in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with androgen receptor inhibitors? (0:05)
2.    Could you tell us a little about the aims and design of the KEYNOTE-641 study? (0:50)
3.    What are the eligibility criteria for this study? (1:23)
4.    How can we overcome the challenge of identifying biomarkers predictive of response to pembrolizumab? (1:55)
5.    What other combined therapeutic approaches involving androgen receptor inhibitors are being investigated in the treatment of mCRPC? (2:51)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Julie Graff has received travel expenses from Sanofi.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
